We have located links that may give you full text access.
CLINICAL TRIAL
JOURNAL ARTICLE
RANDOMIZED CONTROLLED TRIAL
Studies on the effects of the immunosuppressant FK-506 on the high-risk corneal graft rejection.
Yan Ke Xue Bao = Eye Science 2002 September
PURPOSE: To evaluate the clinical efficacy of FK-506 on suppressing high-risk cornea transplantation rejection.
METHODS: In a randomized controlled clinical trial, 56 eyes of 56 patients with high-risk keratoplasty (including total corneal transplantation TCT, total corneal transplantation with circular lamellar sclera CST, vascularization corneal transplantation and corneal retransplantation) were divided into the experimental group and the control group (each with 28 eyes). The experimental group was treated by FK-506 eyedrops (0.5 mg/ml) and TobraDex eyedrops, compared with the control group that was treated by 1% CsA eyedrops and TobraDex eyedrops. In the average 8.1-month follow-up period, the visual acuity, graft transparent duration and Rejection Index (RI) of grafts were observed.
RESULTS: In the follow-up period, the graft rejection rate of the experimental and the control group was 63.6% and 95.2% respectively (chi2 = 4.72, P < 0.05) with significant difference.
CONCLUSIONS: The local application of FK-506 suppressed effectively the graft rejection of corneal transplantation of the patients at high risk.
METHODS: In a randomized controlled clinical trial, 56 eyes of 56 patients with high-risk keratoplasty (including total corneal transplantation TCT, total corneal transplantation with circular lamellar sclera CST, vascularization corneal transplantation and corneal retransplantation) were divided into the experimental group and the control group (each with 28 eyes). The experimental group was treated by FK-506 eyedrops (0.5 mg/ml) and TobraDex eyedrops, compared with the control group that was treated by 1% CsA eyedrops and TobraDex eyedrops. In the average 8.1-month follow-up period, the visual acuity, graft transparent duration and Rejection Index (RI) of grafts were observed.
RESULTS: In the follow-up period, the graft rejection rate of the experimental and the control group was 63.6% and 95.2% respectively (chi2 = 4.72, P < 0.05) with significant difference.
CONCLUSIONS: The local application of FK-506 suppressed effectively the graft rejection of corneal transplantation of the patients at high risk.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app